A controlled trial of oxypertine in tardive dyskinesia.
A study was undertaken to investigate the effects of oxypertine in treating tardive dyskinesia. The design was double-blind, placebo-controlled, between-patient, in 28 patients from whom previous medication was withdrawn, with 14 patients in each group. Treatment was for 4 weeks. Although more oxypertine patients improved than placebo, i.e. 71.4 vs. 50%, the results did not reach statistically significant difference. A further study is planned to increase the overall number of patients in the study, and to lengthen treatment periods.